

Please try another search
Breaking News
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for graves' disease and thyroid eye disease. The company has a license agreement with HanAll Biopharma Co., Ltd. for the rights of intellectual property relating to IMVT-1402 and batoclimab. Immunovant, Inc. was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Name | Age | Since | Title |
---|---|---|---|
Andrew J. Fromkin | 58 | 2019 | Director |
Frank M. Torti | 46 | 2019 | Executive Chairperson of the Board |
Eric Venker | 38 | 2020 | CEO & Director |
Atul C. Pande | 70 | 2019 | Independent Director |
Douglas J. Hughes | 63 | 2019 | Independent Director |
Robert G. Susman | 47 | 2025 | Director |
Jacob B. Bauer | 46 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review